What measures can be used to prevent acute kidney injury?

How to Prevent Acute Kidney Injury

The most effective AKI prevention strategy is optimizing renal perfusion through maintaining mean arterial pressure >65 mmHg (higher in hypertensive patients) using vasopressors, achieving euvolemia with balanced crystalloids while avoiding fluid overload, and implementing rigorous nephrotoxic drug stewardship. 1

Core Prevention Framework

1. Hemodynamic Optimization

Target mean arterial pressure (MAP) >65 mmHg as the foundation of AKI prevention 2, 3. For patients with pre-existing hypertension, consider higher MAP targets as they may require greater perfusion pressure to maintain adequate renal blood flow 4, 2.

• Use norepinephrine as the preferred vasopressor for hemodynamic support 2
• Contrary to older concepts, vasoconstrictors (not vasodilators) are beneficial in AKI, as septic AKI involves intrarenal vasodilation with microcirculatory dysfunction rather than simple vasoconstriction 4

2. Fluid Management Strategy

Adopt a volume-restrictive approach using only balanced crystalloids 4, 2:

• Achieve and maintain euvolemia—both hypovolemia and hypervolemia cause AKI 1, 2
• Avoid fluid overload, which independently leads to AKI 1
• Use diuretics to achieve euvolemia in patients with maintained diuresis, but recognize diuretics are not preventive agents themselves 2
• Recent evidence suggests potential harm from 0.9% saline compared to balanced solutions 1

Critical pitfall: The outdated concept that "more fluid is always better for kidneys" has been definitively disproven 4.

3. Nephrotoxic Drug Stewardship

Implement systematic drug burden assessment and monitoring 1:

Key Principles:

• Use potentially nephrotoxic medications only when needed and for the minimum duration necessary 1
• Monitor kidney function closely in all patients exposed to nephrotoxic agents 1
• Do NOT withhold life-saving nephrotoxic agents (including IV contrast) in critical situations 1

High-Risk Drug Combinations:

• Avoid the "triple whammy": ACE inhibitors/ARBs + diuretics + NSAIDs 1
• Patients receiving ≥3 nephrotoxic drugs daily have significantly increased AKI risk 1
• Consider electronic clinical decision-support systems to identify at-risk patients 1

Specific Drug Considerations:

• ACE inhibitors/ARBs: May cause transient creatinine rise but are often renoprotective long-term; timing of discontinuation and reinitiation in AKI requires careful judgment 1
• NSAIDs: Cause both hemodynamic dysfunction and potential structural injury 1
• Aminoglycosides, acyclovir, VEGF antagonists: Cause direct tubular injury 1

4. Contrast-Associated AKI Prevention

Modern evidence shows contrast-associated AKI risk is substantially lower than previously believed 1:

• Do not withhold indicated contrast imaging in at-risk patients 1, 2
• Limit contrast volume to the minimum necessary 2
• Sodium bicarbonate and N-acetylcysteine are NOT effective based on high-quality trials (PRESERVE, POSEIDON) 1
• The 2012 KDIGO recommendation for NAC has been superseded by newer evidence showing no benefit 5, 1

5. Risk Identification and Monitoring

Identify high-risk patients before procedures or critical illness 6, 2:

• Use clinical and biomarker-based risk scores for specific populations 6
• Monitor serum creatinine and urine output closely 7
• Implement stage-based management with early intervention 4

6. Additional Preventive Measures

• Maintain normoglycemia 7, 6
• Discontinue nephrotoxic agents when possible 7, 3
• Optimize organ function in specific populations (e.g., cardiac surgery patients) 6

What Does NOT Work

Based on high-quality evidence, avoid these ineffective interventions:

• N-acetylcysteine (NAC): No proven benefit despite earlier recommendations 5, 1
• Sodium bicarbonate solutions: PRESERVE trial showed no efficacy 1
• Aggressive fluid loading: Can worsen outcomes through fluid overload 4
• Renal-dose dopamine: Not supported by evidence (general medical knowledge)

Cardiac Surgery-Specific Prevention

For cardiac surgery patients, amino acid infusion is the only pharmacological intervention with proven benefit in high-quality RCTs, reducing AKI by recruiting renal functional reserve and increasing GFR 7. The KDIGO bundle (discontinuing nephrotoxics, monitoring volume/perfusion, avoiding hyperglycemia) showed no significant AKI reduction in pooled meta-analysis 7.

Key Implementation Points

There is currently no approved pharmacological therapy specifically for AKI prevention 6, 2, 3. Prevention relies entirely on:

1. Early risk identification
2. Aggressive hemodynamic optimization
3. Tight volume control
4. Nephrotoxic drug avoidance/monitoring

The most common pitfall is failing to recognize that AKI prevention requires proactive, bundled interventions rather than reactive treatment after injury occurs 4, 3.